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Introduction
Clemizole [1-p-chlorobenzyl-2-(1-pyrrolidinyl) methylbenzimidazole] is a histamine H 1 -receptor antagonist used to treat allergic reactions and dermal diseases (Finkelstein et al., 1960; Jacques and Fuchs, 1960; Wansker, 1962) . Although clemizole is not currently used clinically as a single-agent antihistamine, attention has been paid, recently, to its new therapeutic potential for treating hepatitis C virus (HCV) infection, via inhibiting the binding of NS4B to RNA of HCV (Einav et al., 2008 ) and for the rare but severe genetic disease, Dravet syndrome (Baraban et al., 2013) . Moreover, clemizole strongly inhibits the TRPC5 cation channels (Richter et al., 2014) . However, the effects of clemizole on other ionic currents are not understood, especially the K + currents involved in cardiac repolarization.
Human ether-à-go-go-related gene (hERG or KCNH2) encodes the α-subunit of channel conducting the the rapidly activating delayed rectifier potassium current (I Kr ) that contributes importantly to the repolarization of cardiac action potentials in humans. Dysfunction of I Kr induces long QT syndrome that predisposes affected individuals to lifethreatening arrhythmias. In addition to inherited mutations of hERG, a variety of drugs can impair hERG function, causing long QT syndrome (Sanguinetti and Tristani-Firouzi, 2006; Vandenberg et al., 2012) . The present study examined the effect of clemizole on stably expressed hERG channels, slowly activating delayed rectifier potassium current (I Ks ) (hKCNE1/hKCNQ1) and hK v 1.5 channels in HEK 293 cells and its effect on cardiac repolarization in guinea pig ventricular myocytes and perfused hearts ex vivo. We found that clemizole not only potently blocked hERG channels, but also inhibited hKCNQ1/hKCNE1 and hK v 1.5 channel currents. It increased ventricular action potential duration (APD) and prolonged the corrected QT interval (QTc interval) of the ECG in isolated perfused hearts.
Methods

Cell culture and plasmid transfection
The HEK 293 cell line (Zhang et al., 2010) stably expressing hERG (K v 11.1 or KCNH2) or hK v 1.5 (KCN5A) channels was maintained in DMEM (Hyclone, Shanghai, China) with 400 μg·mL À1 G418 (Sangon Biotech, Shanghai, China) and 10% FBS. HEK 293 cell line stably expressing hKCNQ1/hKCNE1 channels (I Ks ) was cultured in DMEM containing 100 μg·mL
À1
hygromycin B (Invitrogen, Hong Kong, China) and 10% FBS. Cells used for electrophysiology were seeded on glass coverslips. The hERG mutants F656V, Y652A, S631A and S636A in pcDNA3 vector (Tang et al., 2008; Zhang et al., 2010) were transfected into HEK 293 cells in 12-well plates using 6 μL of Lipofectamine 2000 with 3.5 μg of plasmids. Thirty-six to 48 h after transfection, the transfected cells were used for pharmacological studies.
Preparation of guinea pig cardiomyocytes and ex vivo hearts
All animal care and experimental procedures were approved by the Institutional Ethics Committee of Animal Use for Teaching and Research. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Dunkin-Hartley guinea pigs of either sex ((250-300 g), from the Shanghai Laboratory Research Center (Shanghai, China) were used in this study. The animals were housed (3 per cage) under conditions of controlled temperature (23-25°C) and humidity (55-65%) with a 12-h light/dark cycle. The animals had ad libitum access to water and food. The animals were randomly grouped and anaesthetized with sodium pentobarbital (60 mg·kg À1 , i.p.) for cardiac cell isolation or ex vivo heart study. For cardiac cell isolation, the heart was perfused and then its ventricular myocytes were enzymically dissociated as described previously (Li et al., 2002; Liu et al., 2007) . The isolated cardiomyocytes were maintained in a high-K + storage medium (composition in mM): KCl 10, K-glutamate 120, KH 2 PO 4 10, 1.8 MgSO 4 1.8, taurine 10, HEPES 10, EGTA 0.5, glucose 20, mannitol 10, pH adjusted to 7.3 with KOH) at room temperature for 2 h before electrophysiological recording. For the ex vivo heart study, the isolated heart was perfused with Krebs-Henseleit solution (composition in mM): NaCl 118.3, KCl 4.74, CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, glucose 10, NaHCO 3 25; pH adjusted to 7.4 with NaOH), warmed to 37°C and gassed with 95% O 2 and 5% CO 2 , as described previously (Liu et al., 2010) . Briefly, after the animals were anaesthetized, as described above, their hearts were rapidly excised, mounted in a Langendorff system and retrogradely perfused with a pressure of 70 cm H 2 O. Polyethylene tubing
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with a deflated water balloon connected to a pressure transducer was inserted into the left ventricle through a small incision in the left atrium to measure left ventricular systolic pressure (LVSP) and contraction/relaxation velocity (AEdP/ dT). The ECG was recorded with two electrodes placed on the apex and the base of the heart surface (Liu et al., 2010) during the experiments. Hearts with severe cardiac arrhythmias (i.e. frequent ventricular premature beats or ventricular fibrillation >2 min) were excluded from further continuous experiment or data analysis.
The biological signals were recorded using a digital recording system (RM6240, Chengdu Instruments, Chengdu, China) and analysed offline. The QTc interval was calculated with Van de Water's formula ( Van de Water et al., 1989) : QTc = QT À 0.087 × (RR À 1000). This correction formula showed good correlation of QT interval with the cardiac repolarization period (Takahara et al., 2005; Morissette et al., 2015) . After stabilization for 30 min, clemizole was added to the perfusion medium, and its effect on QTc interval was examined.
Electrophysiology
A whole-cell patch clamp technique was employed to record membrane current in voltage-clamp mode and action potentials in current-clamp mode with an EPC-10 amplifier and pulse software (HEKA; Lambercht, Göttingen, Germany) as described previously Liu et al., 2010) . Borosilicate glass electrodes (OD 1.2 mm) were pulled with a Brown-Flaming puller (Model P-97; Sutter Instrument Co., Novato, USA) and had resistances of 1.5-2.5 MΩ when filled with the pipette solution. A 2-M KCl-agar bridge was used as the reference electrode. The potential of the pipette tip was zeroed before the pipette touched the cell. After obtaining a gigaohm seal, the membrane patch was ruptured by a gentle suction to establish a whole-cell configuration. Series resistance (R s ) was compensated by 70-80% to minimize voltage errors. The liquid junction potential (14.3 mV) between pipette solution and bath solution, calculated with the software Clampex, was not corrected during the experiment and was corrected for during analysis of the effects of clemizole on voltage-dependent parameters of the ion channel currents, as specified in the Results and Figure legends . Electrical signals were stored on the hard disk of a Dell computer. Current recordings were conducted at room temperature (22-24°C) and action potential recordings were conducted at 36-37°C. Cells with unstable R s during drug administration were excluded from data analysis.
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data were expressed as mean AE SEM. Statistical comparisons were evaluated with paired or unpaired Student's t-test and with repeated measures ANOVA, as appropriate, followed by the Newman-Keuls test. Non-linear curve fitting was performed using Pulsefit (HEKA) and/or Sigmaplot (SPSS Science, Chicago, IL, USA). A value of P < 0.05 was considered significant. Figure 1A shows the time-dependent effect of clemizole on tail current through hERG channels (I hERG.tail ), recorded in a representative hERG-expressing cell with the original voltage protocol without correcting liquid junctional potential) as shown in the inset (a voltage step to +50 mV for 3 s from a holding potential of À80 mV, then to À50 mV). Clemizole at 0.1 μM in bath solution gradually inhibited the current, and the inhibitory effect was partly reversed by washout for 10 min. Figure 1B demonstrates the family of I hERG upon various depolarization voltages before (control) and after application of 0.1 μM clemizole. Figure 1C illustrates the current-voltage (I-V) relationships of hERG current before and after 0.03, 0.1 and 0.3 μM clemizole, the voltage range (À54.3 mV to +45.7 mV) post-corrected for the liquid junction potential. Both I hERG.step and I hERG.tail were reduced by clemizole in a concentration-dependent manner (n = 8, P < 0.05 vs. control). Figure 1D shows that clemizole-mediated hERG blockade was not voltage dependent. Figure 1E illustrates that the current activation variables (normalized I hERG.tail ) of hERG channels were fitted to a Boltzmann distribution. The half activation potential (V 0.5 ) was not altered by 0.1 μM clemizole (À12.7 AE 1.6 mV for control; À16.4 AE 1.9 mV for clemizole, n = 7, P > 0.05).
Results
Clemizole inhibits hERG channels
The blockade by clemizole of the hERG channels was examined using four hERG mutants: S631A, S636A, Y652A and F656V. The S636 and S631 residues are on the pore helix of the channels and the alanine mutants exhibit decreased channel inactivation. These mutant channels are generally used for determining the role of inactivation in hERG channel blocking (Zhang et al., 1999; Guo et al., 2006) . The F656V and Y652A mutants, in the S6 region, are reported to attenuate hERG channel blockade by several drugs, as these sites constitute the binding site for various drugs (Su et al., 2004; Zhang et al., 2010) . These hERG mutants were therefore used in the present study to analyse the potential molecular determinants of clemizole binding. Figure 2A depicts the wild-type hERG (WT-hERG) and mutant currents recorded in a voltage step as shown in the inset before (control) and after application of 1 μM clemizole. WT-hERG current was almost completely inhibited by clemizole. However, the currents carried by the S631A, F656V and Y652A channels were only partly inhibited by clemizole. The deactivation of F656V current was clearly facilitated by clemizole, which was not observed in WT, S631A or F656V channels. Figure 2B summarises the effects of 1 μM clemizole as an inhibitor of I hERG.tail current, in the WT and mutant channels. to WT-hERG current). Therefore, the residues Ser 631 , Ser 636 , Tyr 652 and Phe 656 may be the major determinants of clemizole binding for blocking hERG channels. The kinetics of inactivation play an important role in high-affinity drug binding to hERG channels (Smith et al., 1996; Spector et al., 1996; Guo et al., 2006) . The hERG channels were fully activated and inactivated by a depolarization voltage step to +50 mV, then a repolarization step to À100 mV for 10 ms to recover the channel from inactivation. The test steps were then clamped to different potentials to observe the time course of the voltage-dependent inactivation in the absence and presence of 0.1 μM clemizole (left panel of Figure 3A ). The inactivation decay time constant was fitted to a mono-exponential equation. The voltage (post-corrected for the junctional potential) dependence of mean values of the time constant is illustrated in right panel of Figure 3A . Over most of the voltage range studied (À34.3 to +15.7 mV ), clemizole (0.1 μM) significantly decreased the inactivation time (n = 8, P < 0.05), compared with control values, suggesting that clemizole accelerated the inactivation of the channel.
The effect of clemizole on steady-state inactivation (availability) of I hERG was determined by a 20 ms voltage steps of À120 to +30 mV from a 4 s prepulse of +40 mV (left panel of Figure 3B ) (Smith et al., 1996; Tang et al., 2008) . The normalized I hERG were fitted to the Boltzmann distribution (right panel of Figure 3B ). The V 0.5 of I hERG inactivation was negatively shifted by 0.1 μM clemizole from À61.1 AE 3.5 mV in control to À67.4 AE 3.2 mV in clemizole (n = 7, P < 0.05).
Recovery of hERG channels from inactivation was determined in the absence (control) and presence of 0.1 μM clemizole using a dual-pulse protocol (left panel of Figure 3C ) as previously described (Spector et al., 1996) . The rising phase of the current was fitted to a mono-exponential function to obtain the recovery time constant. No difference was observed for the recovery time constant of hERG channels from Figure 2 Molecular determinants of hERG channel block by clemizole. (A) Current traces recorded in HEK 293 cells expressing WT, S631A, Y652A and F656V hERG channels, respectively, before (control) and after 1 μM clemizole. Current was elicited by a 3 s voltage step to +50 mV from a holding potential of À80 mV, then back to À50 mV. (B) Inhibition of WT and mutant hERG tail currents by 1 μM clemizole. Data shown are means AE SEM; n = 8 for WT, n = 7 for mutants. *P < 0.05, significantly different from WT. (C) Concentration-inhibition relationships fitted to a Hill equation to obtain IC 50 values of clemizole for inhibiting WT and various mutant hERG channels (n = 7 for each concentration).
inactivation, in the presence of 0.1 μM clemizole (right panel of Figure 3C , n = 6, P > 0.05 vs. control).
Time-dependent inhibition of I hERG by clemizole was determined using a 11 s voltage step to 0 mV from À80 mV to open the channels. The development of I hERG inhibition by 0.1 μM clemizole from the beginning of activation till the end of depolarization step would indicate whether clemizole is an open or closed channel blocker ( Figure 4A ).
The onset of open-channel blocking by 0.1 μM clemizole was assessed with the drug-sensitive current (Gao et al., 2004) , where I C and I D are the currents in the absence and presence of the drug respectively ( Figure 4B ). The initial current blocking of around 14% indicates a small fraction of closed (or tonic) channel blocking, and drug-sensitive current was fitted to a mono-exponential equation with the time constant of 471 AE 59.2 ms (n = 5), which suggests that the inhibition of hERG channels by clemizole involves blocking open channels. However, the potential contribution of tonic blocking and blockade of endogenous K + current by clemizole cannot be excluded.
The development of clemizole blocking of I hERG was further evaluated with an envelope of tails test. Figure 4C shows the time course of the development of clemizole blocking effect on I hERG assessed with the envelope of tails test (Zhang et al., 2010) . Cells were held at À80 mV, pulsed to a depolarizing potential (+30 mV) for variable durations ranging from 50 to 4950 ms and then repolarized to À50 mV. The envelope of tails tests were recorded in the same cell in the absence and presence of 0.1 μM clemizole.
The relative envelope tail current with 0.1 μM clemizole decayed in a pulse-duration-dependent manner ( Figure 4D , n = 7). Tonic blockade of hERG current by clemizole was assessed by the initial value of the relative tail current activated by the envelope protocol. The current at 50 ms prepulse duration was inhibited by 15.1% compared with 47.0% at 4800 ms. So the tonic blocking fraction of hERG channels was about 32%, while open channel blocking was about 68% with 0.1 μM clemizole. This result indicates that clemizole has both closed-and open-channel blocking effects on hERG channels.
Effect of clemizole on I Ks
The effect of clemizole on cardiac I Ks was examined in HEK 293 cells stably expressing hKCNQ1/hKCNE1 plasmids. Figure 5A shows the voltage-dependent I Ks traces recorded in a representative cell with 3 s voltage steps from À80 to +60 mV (10 mV increment), then to À50 mV from a holding potential of À80 mV before and after 3 μM clemizole. I Ks was significantly decreased by clemizole and this effect was partly reversed by washout. Figure 5B displays the I-V relationships of I Ks step current in cells treated with 1, 3 and 10 μM clemizole. The voltage range plotted for the voltagedependent effect of clemizole on I Ks was post-corrected for liquid junction potential. Significant suppression of the current was observed with 1 μM clemizole at +14.7 to +45.7 mV (n = 6, P < 0.05 vs. control), 3 and 10 μM clemizole at À4.3 to +45.7 mV (n = 6, P < 0.05 vs. control). The IC 50 of clemizole for inhibiting human cardiac I Ks step current (at +45.7 mV) shown in Figure 5C had a Hill coefficient of 0.9. No change was observed for current activation (normalized I Ks tail current) with 3 μM clemizole (V 0.5 : 1.5 AE 3.8 mV of control vs. 0.7 AE 4.3 mV, n = 8, P > 0.05)
Effect of clemizole on hK v 1.5 channel current
The effect of clemizole on hK v 1.5 channel current was determined in a stable HEK 293 cell line expressing the KCN5A gene. Figure 6A shows the voltage-dependent hK v 1.5 channel current recorded in a representative cell with the voltage protocol, as shown in the Figure inset, in the absence or presence of 3 μM clemizole. Clemizole significantly suppressed hK v 1.5 channel current, and the effect was reversed upon washout. Figure 6B displays the I-V relationships of hK v 1.5 channel current before (control) and after 3 and 10 μM clemizole. The voltage range plotted for the voltage-dependent effects of clemizole on this current was post-corrected for liquid junction potential. Significant reduction of hK v 1.5 channel current by clemizole, compared with control conditions, was observed at À4.3 to +45.7 mV (n = 6), and the inhibition was voltage-independent ( Figure 6C ). Figure 6D shows the current activation (normalized hK v 1.5 channel tail current) in the absence and presence of 3 μM clemizole and fitted to Raw data (points) were fitted to a mono-exponential equation (solid white line). (C) Envelope of tails protocol and representative hERG current before (control) and after application of 0.1 μM clemizole. Cells were held at a holding potential of À80 mV and pulsed to depolarizing voltage (+30 mV) for variable durations from 50 to 4800 ms in 250 ms increments. I hERG.tail was recorded upon repolarization to À50 mV. (D) A plot of relative tail current with 0.1 μM clemizole versus the depolarizing duration. The time-dependent decay in relative tail current was fitted to a mono-exponential equation (mean AE SEM, n = 6).
the Boltzmann function. The V 0.5 of hK v 1.5 channel activation was not altered by clemizole (V 0.5 : 1.1 AE 0.8 mV of control vs. À1.3 AE 0.6 mV, n = 7, P > 0.05). The IC 50 of clemizole for inhibiting hK v 1.5 channel current (at +45.7 mV) shown in Figure 6E had a Hill co-efficient of 1.1.
Effect of clemizole on ventricular action potentials
Whether the inhibition of I hERG and I Ks by clemizole leads to a prolongation of ventricular APD was determined in guinea pig ventricular myocytes (37°C). Figure 7A illustrates the ventricular action potentials recorded (2 Hz) in a representative myocyte before (control) and after application of 0.1, 0.3, 1 and 3 μM clemizole. APD was progressively prolonged with increasing concentrations of clemizole. The effect was partially recovered on drug washout. Figure 7B shows the individual and mean values of APD at 50 and 90% repolarization (APD 50 and APD 90 ) in ventricular myocytes of guinea pig hearts. Clemizole (0.1-3 μM) prolonged both APD 50 and APD 90 (n = 5-10), compared with control. Changes in resting membrane potential and action potential amplitude were not observed over this concentration range of clemizole (data not shown), suggesting that clemizole did not significantly inhibit sodium channels or the inward rectifier K + current (I K1 ).
Clemizole prolongs ECG QTc interval in ex vivo guinea pig hearts
It is generally believed that the suppression of I hERG and/or I Ks and ventricular APD prolongation implies a potential for cardiac toxicity, that is, increasing the QT interval of the ECG (Yang et al., 2004; Hauser et al., 2005; Takahara et al., 2006) . To investigate whether clemizole has the potential of increasing QT interval, we determined the effect of clemizole on the QTc interval of ECG and other parameters in guinea pig isolated and perfused hearts. Figure 8A shows the ECG traces and LVSP and the pressure velocity during heart contraction/relaxation (dP/dT) in a representative experiment in a heart before and after perfusion with 1 μM clemizole for 10 min. Clemizole decreased the heart rate and prolonged QT interval. The average values of heart rate and QTc interval are shown in Figure 8B . Heart rate was decreased by 0.3 and 1 μM clemizole, while QTc interval was increased with these concentrations. However, the width of the QRS complex and the cardiac contractile parameters LVSP and +dP/dT were not changed by any concentration of clemizole ( Figure 8C ).
Discussion
Clemizole is a histamine H 1 -receptor antagonist drug, first developed in the 1950s (Zierz and Greither, 1952; Naranjo and De Naranjo, 1958) . Early studies showed that clemizole has a high antihistamine specificity with low toxicity in acute and chronic observations in animal experiments (Finkelstein et al., 1960) . Clemizole is clinically used for allergic rhinitis (Jacques and Fuchs, 1960) and pruritus of dermatoses (Wansker, 1962; Osment and Broyles, 1963) . Clemizolepenicillin is widely employed for antiluetic therapy (Kleinhans, 1971; Kirwald and Montag, 1999; Heise, 2004) . In addition, an earlier study in dogs demonstrated that clemizole effectively converted atrial flutter induced by circus movement into sinus rhythm by increasing the atrial refractory period without significant reduction in conduction velocity (Mendez et al., 1969) . A previous study with high-throughput screening identified 18 compounds that inhibit binding of the viral protein NS4B to RNA and found that clemizole inhibited HCV RNA replication in host cell culture with little toxicity, suggesting that clemizole is a promising candidate for the pharmaceutical development of anti-HCV compounds (Einav et al., 2008) . The antiviral effect of clemizole was found to be remarkably synergized by combination with either interferon or ribavirin and the HCV protease inhibitors VX950 and SCH503034 (Einav et al., 2010) . Although clemizole has a short plasma half-life with rapid biotransformation, the predominant glucuronide and dealkylated metabolites in human still retain synergistic anti-HCV activity (Nishimura et al., 2013) . A phase 1 clinical trial (NCT00945880) of clemizole has been carried out to evaluate safety and tolerability to treat hepatitis C (https://www.clinicaltrials.gov/ct2/ show/NCT00945880). Although there is no published clinical trial data available, clemizole might have the potential for long-term clinical use to treat patients with hepatitis C in the future.
In this study, we have demonstrated that clemizole inhibited cardiac hERG (encoding for cardiac I Kr ) and hKCNQ1/hKCNE1 (encoding for cardiac I Ks ) channels, and also hKv1.5 (encoding for cardiac I Kur ) channels, prolonged APD in guinea pig ventricular myocytes and QTc interval in ex vivo guinea pig hearts. These effects may account for its antiarrhythmic effect of converting atrial flutter into sinus rhythm observed in anaesthetized dogs (Mendez et al., 1969) . However, these effects may also imply that clemizole has cardiac toxicity and has the potential to cause long QT syndrome or Torsade de pointes (TdPs).
It is well documented that drugs that prolong QTc interval, in general, by blocking I Kr or hERG channels although patients with drug-induced TdPs may have additional cardiac risk factors (Sanguinetti and Tristani-Firouzi, 2006; Gupta et al., 2007; Isbister and Page, 2013) . We found that clemizole decreased the current carried by hERG channels stably expressed in HEK 293 cells, in a concentration-dependent manner with an IC 50 of 70 nM. The inhibition was related to blocking closed and open channels and accelerating hERG channel inactivation without affecting steady-state availability or recovery. The blocking properties of clemizole for hERG channels are similar to those observed with the selective oestrogen receptor modulator, raloxifene (Liu et al., 2010) .
The blocking effect of clemizole was reduced by >10-fold in the mutant hERG channels, S631A and S636A, which exhibit deficient channel inactivation, suggesting that the inactivation is required for high-affinity blockade of the channel by clemizole, which is similar to the selectiveserotonin re-uptake inhibitor fluvoxamine (Milnes et al., 2003) , cocaine (Guo et al., 2006) and the calmodulin inhibitor W-7 (Zhang et al., 2010) . The hERG mutants Y652A and F656V also showed markedly reduced (20-to 40-fold) inhibition of hERG current by clemizole. This may suggest that the binding of clemizole is involved at Tyr 652 and Phe 656 , and that the hydrophobicity of the side chain residues of Tyr 652 and Phe 656 is related to the channel sensitivity to clemizole.
Therefore, Y652 and F656 are likely to be important sites for the binding of clemizole to hERG channels, as has been already observed for cisapride, terfenadine, MK-499 (Fernandez et al., 2004) and fluvoxamine (Milnes et al., 2003) . Although these results indicate that these four residues S631, S636, 
Figure 8
Effects of clemizole on ECG and contractile function in guinea pig isolated perfused hearts. (A) Representative ECG and heart contractile parameters (LVSP and dP/dT) recorded in a heart before (control) after 1 μM clemizole application. (B) Heart rates (BPM) and QTc interval (ms) in hearts before and after treatment with 0.1, 0.3 and 1 μM clemizole. Data shown are means AE SEM (n = 7). *P < 0.05, significantly different from control). (C) Changes in QRS complex, LVSP and +dP/dT after 0.1, 0.3 and 1 μM clemizole. Data shown are means AE SEM; n = 7, P > 0.05, significantly different from vehicle).
Y652 and F656 are major molecular determinants of clemizole blockade of the channel, the possibility of binding to other amino acids cannot be excluded. A whole new series of experiments would be required to carry out an alanine scan of the whole S6 segment (Kamiya et al., 2006) to assess the binding of clemizole to other amino acids. The drug-induced negative chronotropic effect is usally related to the inhibition of Ca 2+ current (I Ca ) and/or pacemaker current (i.e. funny current I f , encoded by HCN2/HCN4 channels, and the hyperpolarization-activated cyclic nucleotide-gated ion channels). In this study, we found that clemizole significantly reduced heart rate in guinea pig hearts ex vivo. However, the effect seemed to be unrelated to the mechanisms described above, because clemizole increased guinea pig ventricular APD, prolonged QTc interval without reducing the cardiac contractile function parameters LVSP and AEdP/dT and did not show any inhibition of I f channels in HEK 293 cells expressing HCN2 or HCN4 channels with 1 μM clemizole ( Figure S1 ). The likely cause of the heart rate reduction by clemizole is the I Kr /hERG channel blockade. This is supported by an earlier report, in which E4031 blocked I Kr and decreased sinus rhythm in adult mouse sinoatrial node cells (Clark et al., 2004) . Drug effects on I Ks and QT interval are not well recognized. However, norfluoxetine (a selective serotonin reuptake inhibitor) prolonged QT interval in a patient with KCNQ1 mutation, and therefore, I Ks blockade may also be involved in drug-induced long QT syndrome when repolarization reserve is reduced (Veerman et al., 2013) . In the present study, we found that clemizole decreased hKCNQ1/hKCNE1 channels expressed in HEK 293 cells. The IC 50 of clemizole for inhibiting I Ks was 2.7 μM, which may also contribute to the prolongation of APD and QT interval in guinea pig ventricular myocytes and guinea pig isolated hearts. Clemizole decreased hK v 1.5 channel current expressed in HEK 293 cells with an IC 50 of 3.7 μM, suggesting that clemizole may be an non-selective channel blocker. In addition to blockade of cardiac K + currents, a recent study demonstrated that clemizole might be a potential TRPC5 channel blocker (Richter et al., 2014) . The TRPC channels are present in many different types of cells and tissues in mammals, including humans. In addition to the regulation of various cellular physiological functions, they mediate a range of patho-physiological processes, for example, cardiac hypertrophy and fibrosis, vascular disorders, cancer, inflammation and neurodegenerative disorders and thus are considered to be pharmacological targets (Pena and Ordaz, 2008; Kaneko and Szallasi, 2013; Nilius, 2013) . Although a great effort has been made to identify selective TRPC channel blockers, no selective antagonists are available for clinical trials. The general TRPC channel blocker, SKF-96365, also inhibited the voltage-gated sodium current I Na (Chen et al., 2015) , the voltage-gated calcium current I Ca.L (Franzius et al., 1994) and I Ca.T (Singh et al., 2010) , several cardiac potassium currents, including I hERG , I Ks , K ir 2.1/I K1 and K v 4.3/I to ) and induced the long QT syndrome (Liu et al., 2016) . The report that clemizole might be a potent blocker of TRPC5 channels (Richter et al., 2014 ) is attractive and interesting. Nonetheless, the present study demonstrated that clemizole decreased several cardiac K + channels, especially hERG channels, and caused a prolongation of QT interval.
While Pyr3 is a selective antagonist of TRPC3 channels (Kiyonaka et al., 2009) , it is still experimental (Munakata et al., 2013) . Therefore, further effort is needed to develop more selective TRPC inhibitors for novel therapeutic use. Although clemizole has been developed for many years, it is not administered systemically in clinical use, as it is used topically for allergic rhinitis (Jacques and Fuchs, 1960) , allergic reactions and dermal diseases (Finkelstein et al., 1960; Jacques and Fuchs, 1960; Wansker, 1962) . Therefore, cardiac toxicity (QTc prolongation/TdP with clemizole) has not been reported. The more recent studies on clemizole have uncovered its therapeutic potential for treating HCV infection (Einav et al., 2008) and the rare but severe genetic disease, Dravet syndrome (Baraban et al., 2013) and its blocking effect on TRPC5 ion channels (Richter et al., 2014) . This study demonstrated that clemizole blocked I hERG with a IC 50 of 70 nM, which is 10-fold lower than the plasma level (767 nM) found in patients in the clinical trial for treating hepatitis C (https:// www.clinicaltrials.gov/ct2/show/NCT00945880; Nishimura et al., 2013) and the IC 50 (1 μM) for blocking TRPC5 channels (Richter et al., 2014) . The high sensitivity of clemizole for blocking I hERG and inhibiting I Ks (IC 50 of 2.7 μM) implies that this compound has potential to cause QTc prolongation and /or TdP. Therefore, its potential for cardiac toxicity must be considered when it is used long-term to treat HCV infections. Similarly, interpretation of experimental results obtained in native cardiac cells using clemizole as a blocker of TRPC channels, must allow for its effects on hERG and other K + channels.
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http://doi.org/10.1111/bph.13679 Figure S1 Effects of clemizole on HCN2 and HCN4 channels, stably expressed in HEK 293 cells. A. HCN2 channel current traces recorded with the voltage protocol shown above the traces in the absence (control) and presence of 1 μM clemizole (8 min). Clemizole had no effect on HCN2, and similar results were obtained in additional 3 sets of cells. B. HCN4 channel current traces recorded with the voltage protocol shown above the traces in the absence (control) and presence of 1 μM clemizole (8 min). Clemizole had no effect on HCN4 channel current, and similar results were obtained in additional 3 sets of cells.
